Balancing the opportunities and challenges of developing companion diagnostics: Part 2 of 2

• Life Sciences
• Infographics

Upper Payment Limits (UPLs) explained

Regulatory shifts create new challenges for pharmaceutical stakeholders. Four states now have PDABs empowered to set UPLs for public payers, and three states...

• Life Sciences
• CRA Insights

The evolving vaccine landscape: Insights from the 6th ESCMID Conference on Vaccines

The conference brought together the vaccine community and stakeholders, including industry representatives, clinicians, regulators, policymakers, academics,...

• Life Sciences
• CRA Hosted Event

• January 13, 2026
• San Francisco, CA

What Happens if U.S. Pharmaceutical Prices Become the World’s Benchmark?

The U.S. Most Favored Nation (MFN) Executive Order could upend global drug pricing as we know it. Some manufacturers are now vowing to launch only at U.S....